This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

WCLC, TORONTO, 23-26 September 2018

Oncologist Treatment Considerations and Selection in EGFR M+ NSCLC

Thomas Wehler, Bernd Tischer, Steffen Reisgys, Vera Hirsh

Wehler WCLC poster

RELATED MATERIALS

Learn more about the science behind this poster in the videos, papers and other materials below.

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

Hirsh V. Ther Adv Med Oncol. 2018; 10: 1758834017753338

FOR HEALTHCARE PROFESSIONALS ONLY.

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.

The information contained herein does not necessarily reflect the content of the approved Canadian product monograph.